What are FDA's Expectations from Contract Manufacturers?

Recommendation
15-17 October 2025
In a four-page Warning Letter to a contract manufacturer who produces semi-solid OTC products, the FDA criticized amongst others:
- Missing tests of starting and finished products
- Lacking supplier qualification
- Non-existent CAPA measures with regard to a wrong primary packaging
Besides, further critics addressed a non-existent programme for Ongoing Process Verification and lacking first validation (Process Performance Qualification).
FDA's statements on the responsibilities of a contractor are particularly interesting. For the FDA, contractors are an "extension" of the actual manufacturer. Regardless of agreements with the products' owner, the contractor is responsible for the quality of products, FDA says.
The Chinese manufacturer argued to be a cosmetics manufacturer with no intention of manufacturing any drug products. The FDA countered this argument with the definition of a drug product ... The FDA urgently recommended engaging a consultant and explicitly mentioned that the company has to comply with the CGMP anyway. According to the FDA, the executive management remains responsible for complying with CGMP and fully resolving all deficiencies.
Please also read the complete FDA Warning Letter to Hangzhou Karic Commodities Co., Ltd.
Related GMP News
08.10.2025Risk-based Determination of the Scope and Frequency of Audit Trail Reviews
01.10.2025Decentralised Manufacturing: New UK Framework in Operation
24.09.2025Responsibilities for the Audit Trail (Review)
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
17.09.2025Dealing with Systems without Audit Trail Functionality